Patents by Inventor Robert Sandrock

Robert Sandrock has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for expanding, identifying, characterizing and enhancing potency of mammalian-derived glial restricted progenitor cells
    Patent number: 10351823
    Abstract: Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
    Type: Grant
    Filed: November 9, 2010
    Date of Patent: July 16, 2019
    Assignee: Q THERAPEUTICS, INC.
    Inventors: Robert Sandrock, James T. Campanelli, Deborah A. Eppstein
  • METHODS AND COMPOSITIONS FOR EXPANDING, IDENTIFYING, CHARACTERIZING AND ENHANCING POTENCY OF MAMMALIAN-DERIVED GLIAL RESTRICTED PROGENITOR CELLS
    Publication number: 20190032010
    Abstract: Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
    Type: Application
    Filed: September 19, 2018
    Publication date: January 31, 2019
    Applicant: Q Therapeutics, inc.
    Inventors: Robert SANDROCK, James CAMPANELLI, Deborah EPPSTEIN
  • Methods and Compositions for Expanding, Identifying, Characterizing and Enhancing Potency of Mammalian-Derived Glial Restricted Progenitor Cells
    Publication number: 20120230963
    Abstract: Methods for producing a population of human-derived glial restricted progenitor cells (GRPs) with decreased potentially unintended or undesired cellular phenotypes and/or decreased standard deviation in the cells of the population are provided. Also provided are antibody panels and gene expression profiles to characterize GRPs and a method for its use in characterizing GRP cells. In addition methods for use of these GRP cells to generate astrocytes and/or oligodendrocytes, to re-myelinate neurons and to treat glial cell related and other neurodegenerative diseases or disorders or injuries or damage to the nervous system are provided. A method to manufacture neural cells depleted of A2B5 positive cells is also provided.
    Type: Application
    Filed: November 9, 2010
    Publication date: September 13, 2012
    Applicant: Q Therapeutics, Inc.
    Inventors: Robert Sandrock, James T. Campanelli, Deborah A. Eppstein